Lovely Meds Review

Our assessment

Lovely Meds does the single most useful thing a compounded seller can do: it prints all four commitment lengths in one table on the product page. The cheap headline and the month-to-month rate sit side by side, instead of one hiding the other. It also sells the FDA-approved once-daily oral pill openly, at a published cash price, which almost nothing else here does. It just charges roughly double what Alloy, ZipHealth, Sesame Care and Shapely publish for the identical branded tablet. Against all that: an FDA warning letter in September 2025 over how it described its compounded drugs. Also no named pharmacy, no named prescriber, no state list, and two of its own legal documents naming two different clinical groups.

Read the plan table, not the headline

Both compounded product pages open with a figure introduced by the word From. On most sites that's where the disclosure stops and you find out at checkout that the number assumed a year. Here, a few hundred pixels down the same page, sits a table headed Plan Length and Price / Month. All four tiers are in it: one month, three months, six months, twelve months, with the twelve-month row badged Best Value.

That table is what makes the hero figure honest rather than merely accurate. The From price is the twelve-month rate, and the page says so somewhere you'll actually reach. If you don't want to commit for a year, the one-month row is your price.

The same table settles the dose question in one line: all doses cost the same, and what changes between tiers is how long you commit, not how much drug you get. Titrating upward won't raise your bill.

It sells the branded oral pill, at about twice what four others charge

Foundayo is orforglipron, a once-daily tablet, FDA-approved and not compounded. Lovely Meds gives it a real product page with a real price, badged In stock, Rx, FDA-Approved and FSA/HSA eligible, with a line underneath saying the figure covers a one-month supply. Most sellers manage nothing like that for a branded product, and it means you can compare without starting an intake.

The comparison is the interesting part. Alloy, ZipHealth, Sesame Care and Shapely all publish a price for the same branded pill, all four publish the same figure, and that figure is roughly half of what Lovely Meds asks. Those four were read on 5 and September 2026, and this page. It is a live spread between five current prices, not a stale number sitting beside a fresh one.

None of the five is quoting a different product. It's one manufacturer's tablet, and the gap between the cheapest and dearest route to it is wider than the gap between many compounded sellers here. If the branded oral is what you want, this is the one to check the others against, not the one to buy from.

One more thing about that page: unlike the compounded pages, it publishes no plan ladder and no dose ladder. Sesame Care prints a six-step ladder for the same drug, with the figure rising as the dose does. Lovely Meds prints one number introduced by the words Starting at, and never says what it starts from.

The FDA letter, and what the site says now

In September 2025 the FDA issued a warning letter to Lovely Meds, Inc. dba Lovely Meds. The subject was advertising, not manufacturing. The agency quoted two claims from the website: that the compounded products contained the same active ingredient as Wegovy and Ozempic, and as Zepbound and Mounjaro. Those claims implied the compounded products were the same as an FDA-approved product when they are not, which misbrands them under the Federal Food, Drug, and Cosmetic Act.

That wording is gone from the homepage and both compounded product pages, the three places a shopper would meet it. Other pages on the site weren't read, so this covers those three and no more.

What sits there now is close to the opposite: a standing line under the price saying compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. That is the disclosure the letter asked for, in the place it needed to be.

A letter is a disclosure, not a disqualification, and it doesn't move where Lovely Meds sits here. It's a fact you're entitled to have in front of you, and the full text is public if you want it.

Two legal documents, two different clinical groups

The Terms say Lovely Meds operates a technology platform, and that clinical evaluations and prescribing decisions are made independently by licensed healthcare providers affiliated with Beluga Health, P.A.

The privacy policy tells a different story. It says Lovely Meds, Inc. contracts with The Pharmacy Hub, describing it as an independent medical group that provides clinical telehealth services, and adds that Lovely Meds is also affiliated with Wasef Health, which supply medicinal products. One document names Beluga Health as the clinical group; the other names two other companies, one of them in the same role.

Wasef Health turns up repeatedly in this comparison. Cora Health, Trava Health, Effecty, Gimme Care, Ondra Health and Harper Meds all sit behind it, which is worth knowing if you were treating those sellers as independent second opinions.

That is why the pharmacy question goes unanswered here rather than answered. The Pharmacy Hub is a pharmacy, and this site calls it a medical group. A name attached to the wrong role tells you less than a name attached to the right one, and the product page's own answer is the unhelpful one: prepared by state-licensed U.S. compounding pharmacies, plural and anonymous.

What you can't find out before the intake

There is no list of the states Lovely Meds operates in. The FAQ acknowledges the question and hands it back: availability depends on state regulations and clinician licensing, and the platform will tell you whether services are available in your state. The Terms add only that products are available where the provider group is authorized to operate. Nothing on the homepage, either priced page, the Foundayo page, the FAQ, the privacy policy or the Terms names a single state.

There is no named prescriber either. No medical director, no clinical lead, nobody you could look up in a state licensing database before handing over your details. Cora Health and Midi Health both name theirs.

And there is no statement about a membership or program fee in either direction. The words membership and subscription appear on neither priced page, the Foundayo page or the FAQ. That is silence, not a no, so ask before you pay.

A small thing, but it belongs here: the copyright line on the Terms reads 2025. In September 2026 that's a page nobody has revisited in a while, on a site whose regulator asked it to revisit its wording.